Jack Spira
YOU?
Author Swipe
View article: Comparison of sfilm-FS and TACHOSIL in patients undergoing liver surgical procedures requiring hemostasis – A phase 1/2, randomised, controlled study
Comparison of sfilm-FS and TACHOSIL in patients undergoing liver surgical procedures requiring hemostasis – A phase 1/2, randomised, controlled study Open
This Phase I/II randomized, controlled, multicenter study aimed to evaluate the safety and efficacy of sFilm-FS compared to Tachosil® in patients undergoing elective liver surgery requiring hemostasis at the liver surface. sFilm-FS is a ne…
View article: Supplementary Figure 1 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Supplementary Figure 1 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
PDF file - 4200K, Supplementary Figure 1 (A) MM.1R and RPMI-8226 MM cells were treated with mel-flufen {1μM and 3μM, respectively} for 24h; protein lysates were subjected to immunoblotting using indicated antibodies. (B) MM1.R cells were t…
View article: Supplementary Figure 1 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Supplementary Figure 1 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
PDF file - 4200K, Supplementary Figure 1 (A) MM.1R and RPMI-8226 MM cells were treated with mel-flufen {1μM and 3μM, respectively} for 24h; protein lysates were subjected to immunoblotting using indicated antibodies. (B) MM1.R cells were t…
View article: Supplementary Figure Legend from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Supplementary Figure Legend from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
PDF file - 66K
View article: Data from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Data from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
Purpose: The alkylating agent melphalan prolongs survival in patients with multiple myeloma; however, it is associated with toxicities and development of drug-resistance. Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen…
View article: Supplementary Figure Legend from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Supplementary Figure Legend from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
PDF file - 66K
View article: Supplementary Figure 2 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Supplementary Figure 2 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
PDF file - 281K, Supplementary Figure 2 MM.1S cells were treated with indicated concentrations of melphalan or mel-flufen for 4h. The cells were harvested and subjected to alkaline comet assay, and the fluorescent images were visualized (e…
View article: Data from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Data from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
Purpose: The alkylating agent melphalan prolongs survival in patients with multiple myeloma; however, it is associated with toxicities and development of drug-resistance. Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen…
View article: Supplementary Figure 2 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Supplementary Figure 2 from <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Open
PDF file - 281K, Supplementary Figure 2 MM.1S cells were treated with indicated concentrations of melphalan or mel-flufen for 4h. The cells were harvested and subjected to alkaline comet assay, and the fluorescent images were visualized (e…
View article: Effects of the colour and design of a new pelvic examination chair on comfort during gynaecological examination
Effects of the colour and design of a new pelvic examination chair on comfort during gynaecological examination Open
Objectives: The main question was whether the colour of a new design of pelvic examination chair could affect how the examination procedure was perceived. A prototype was constructed without vertical leg support and with built-in heating i…
View article: Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry Open
Summary Aim This 4‐week open‐label observational study describes the effect of introducing a microtablet dose dispenser and adjusting doses based on objective free‐living motor symptom monitoring in individuals with Parkinson's disease ( P…
View article: Responsiveness of the Endometriosis Health Profile-30 questionnaire in a Swedish sample: an observational study
Responsiveness of the Endometriosis Health Profile-30 questionnaire in a Swedish sample: an observational study Open
The EHP-30 is responsive to improvement on all core scales and is acceptable, understandable, and applicable in this Swedish sample.
View article: Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment Open
In the PD population, following levodopa/carbidopa microtablet administration in fasting state, the Cmax and AUC0-4/dose were found to be higher compared with results from a previous study in young, healthy subjects. A large between subjec…
View article: Preclinical activity of melflufen (J1) in ovarian cancer
Preclinical activity of melflufen (J1) in ovarian cancer Open
Ovarian cancer carries a significant mortality. Since symptoms tend to be minimal, the disease is often diagnosed when peritoneal metastases are already present. The standard of care in advanced ovarian cancer consists of platinum-based ch…
View article: Melphalan‐flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma
Melphalan‐flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma Open
Background: Chemotherapy options in advanced urothelial carcinoma (UC) remain limited. Here we evaluated the peptide‐based alkylating agent melphalan‐flufenamide (mel‐flufen) for UC. Methods: UC cell lines J82, RT4, TCCsup and 5637 were tr…
View article: Construction of a levodopa-response index from wearable sensorsfor quantifying Parkinson’s disease motor functions : Preliminary results
Construction of a levodopa-response index from wearable sensorsfor quantifying Parkinson’s disease motor functions : Preliminary results Open
Construction of a levodopa-response index from wearable sensorsfor quantifying Parkinson’s disease motor functions : Preliminary results
View article: Levodopa/carbidopa microtablets in Parkinson disease - pharmacokinetics and blinded motor assessment
Levodopa/carbidopa microtablets in Parkinson disease - pharmacokinetics and blinded motor assessment Open
The aim of this study was to characterize the levodopa and carbidopa plasma concentration in relation to blinded motor function ratings. This is a part of a study where a Multimodal motor Symptoms Quantification (MuSyQ) platform consisting…
View article: Quantification of upper limb motor symptoms of Parkinson's disease using a smartphone
Quantification of upper limb motor symptoms of Parkinson's disease using a smartphone Open
Objective: The aim of this study is to develop and evaluate methods for quantifying motor symptoms in Parkinson’s disease (PD) using combined upper limb motor test data collected during tapping and spiral drawing tasks by a smart phone. Ba…